C07K 14/4708
Duchenne dystrophy
Official title: {Duchenne dystrophy}
C07K14/4708 (Duchenne dystrophy) appears on 111 US grants and 208 published applications in this corpus.
Search patents in C07K- Granted patents
- 111
- Published applications
- 208
- Assignees
- 100
- Inventors
- 381
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 5 |
| 2003 | 2 | 2 |
| 2004 | 1 | 1 |
| 2005 | 1 | 2 |
| 2006 | 1 | 2 |
| 2007 | 1 | 1 |
| 2008 | 2 | 5 |
| 2009 | 1 | 1 |
| 2010 | 1 | 1 |
| 2011 | 3 | 3 |
| 2012 | 0 | 4 |
| 2013 | 3 | 4 |
| 2014 | 2 | 3 |
| 2015 | 1 | 6 |
| 2016 | 4 | 7 |
| 2017 | 4 | 9 |
| 2018 | 3 | 7 |
| 2019 | 10 | 18 |
| 2020 | 9 | 11 |
| 2021 | 2 | 15 |
| 2022 | 6 | 12 |
| 2023 | 6 | 26 |
| 2024 | 10 | 16 |
| 2025 | 7 | 27 |
| 2026 | 10 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- Microdystrophin gene therapy constructs and uses thereof4 Aug 2026US 12,697,399 B2REGENXBIO Inc.
- Trophin genome editing for treating Duchenne Muscular Dystrophy (DMD)14 Jul 2026US 12,680,100 B2The Trustees of the University of Pennsylvania
- Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs16 Jun 2026US 12,655,427 B2Research Institute At Nationwide Children's Hospital
- Novel regulatory cassettes for specific expression of genes in muscle stem cells8 Oct 2026US 2026/0306674 A1University of Washington
- Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs3 Sep 2026US 2026/0258419 A1Research Institute At Nationwide Children's Hospital
- Engineered muscle targeting compositions27 Aug 2026US 2026/0250713 A1Massachusetts Institute of Technology
- Crispr/cas-based base editing composition for restoring dystrophin function20 Aug 2026US 2026/0242782 A1Duke University
- Engineered dystrophin proteins with reduced immunogenicity6 Aug 2026US 2026/0226120 A1University of Washington
Most cited
By later US patents
- Multiplex genomic DNA amplification for deletion detection131US 5,582,989 ABaylor College of Medicine · 1996
- Pharmaceutical composition for treatment of Duchenne muscular dystrophy124US 6,727,355 B2JCR Pharmaceuticals Co., Ltd. · 2004
- Myogenic vector systems114US 5,298,422 ABaylor College of Medicine · 1994
- Adenovirus vectors92US 5,994,132 AUniversity of Michigan · 1999
- Expression vector systems and method of use89US 5,756,264 ABaylor College of Medicine · 1998